Viridian Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Viridian Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Viridian Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Viridian Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Viridian Therapeutics Inc (Viridian), formerly miRagen Therapeutics, focuses on the discovery and development of medicines for serious and rare diseases. The company’s major products in development are VRDN-001 and VRDN-003, which are aimed at treating thyroid eye disease (TED), and a portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, for autoimmune diseases. The company’s lead product candidate, VRDN-001, is an intravenous humanized monoclonal antibody targeting IGF-1R, and VRDN-003 is for subcutaneous administration, both aimed at treating thyroid eye disease (TED). The company develops novel RNA-based therapeutics, with a core focus on therapeutic antibodies and their roles in diseases. Viridian is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
221 Crescent Street, Suite 103A, Waltham, Massachusetts, 02453
Website
www.viridiantherapeutics.com
Telephone
1 302 6587581
No of Employees
252
Industry
Medical Equipment
Ticker Symbol & Exchange
VRDN (NASD)
Revenue (2024)
$70.8M
23359.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-26.9%
(2024 vs 2023)
Market Cap*
$2.2B
Net Profit Margin (2024)
XYZ
99.5%
(2024 vs 2023)
* As of and is in US$
Viridian Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| VRDN-001 - Thyroid Eye Disease (TED) - Intravenous |
| VRDN-003 - Thyroid Eye Disease (TED) - Discovery Stage |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company announced a partnership with Enable Injections to utilize the enFuse technology. |
| 2022 | New Product Approvals | In January, the company announced the FDA clearence for Investigational New Drug Application for VRDN-002. |
| 2022 | New Product Approvals | In January, the company submitted Investigational New Drug Application for VRDN-002 to US FDA. |
Competitor Comparison
| Key Parameters | Viridian Therapeutics Inc | Roche Holding AG | Amgen Inc | Argenx SE | Alumis Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | Netherlands | United States of America |
| City | Waltham | Basel | Thousand Oaks | Amsterdam | San Francisco |
| State/Province | Massachusetts | Basel-Stadt | California | Noord-Holland | California |
| No. of Employees | 252 | 112,774 | 31,500 | 1,863 | 225 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stephen Mahoney | Chief Executive Officer; Director; President | Executive Board | 2023 | 53 |
| Seth Harmon | Chief Financial Officer | Senior Management | 2023 | 44 |
| Thomas Beetham | Chief Operating Officer | Senior Management | 2023 | 54 |
| Jennifer Tousignant | Chief Legal Officer | Senior Management | 2024 | 52 |
| Radhika Tripuraneni | Chief Medical Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer